Written in Blood

Written in Blood

Research from recent issues of Blood

Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis

Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...
WIB_icon

Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP

Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...
WIB_icon

MRD Negativity Measured Via Next-Generation Sequencing Predicts Long-Term Survival in Myeloma

Measuring minimal residual disease (MRD) status using next-generation sequencing (NGS) represented a prognostic biomarker for survival in patients with multiple myeloma (MM), according to...
WIB_icon

Next-Generation Sequencing MRD Assessment Valuable Tool in AML Management

Assessing minimal residual disease (MRD) using next-generation sequencing (NGS) in patients with acute myeloid leukemia (AML) prior to undergoing allogeneic hematopoietic cell transplantation (alloHCT)...
WIB_icon

Risk of Thrombosis in Patients With Cancer and Implanted Ports

Although patients with solid-tumor cancers and implanted ports have a high risk for venous thromboembolism (VTE), guidelines advise against routine thromboprophylaxis, given the wide...
WIB_icon

Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia

Since 2001, more patients with leukemia are receiving hospice services, which has been associated with improved quality of life, according to an analysis published...
WIB_icon

Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia

Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...
WIB_icon

Insurance Status Contributes to Survival Disparities in Follicular Lymphoma

Patients with follicular lymphoma (FL) who have private health-care insurance live longer than uninsured patients or those who are enrolled in Medicare, according to...
WIB_icon

No Benefit, but Excess Toxicity, With Rivaroxaban for Patients With High-Risk Antiphospholipid Syndrome

Rivaroxaban and other direct oral anticoagulants are used as an alternative to warfarin for the prevention of thromboembolism, but data do not support routine...
WIB_icon

Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML

Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...
Advertisement

Current Issue

November 2018, Volume 4, Issue 13

This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.